Home – Page 14 – The Cancer Letter

Issue 10 - Mar 6, 2020

TCL49-10 (232 downloads)

Coronavirus vs. oncology: Meeting cancellations, travel restrictions, fears about drug supply chain
Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.
Moffitt execs were made aware of Howard McLeod’s China activities, ousted researcher’s attorney says
Howard McLeod, one of the six researchers ousted at Moffitt Cancer Center under allegations of undisclosed conflicts of interest stemming from their work in China, is publicly disputing his former employer’s characterization of his involvement with academic institutions there.
An Appreciation
Clara Bloomfield, blood cancer expert and destroyer of glass ceilings, dies at 77
By Electra D. Paskett, Ph.D.
In 1989, I joined Cancer and Leukemia Group B and was introduced into the clinical trials world and a mighty force for good, Dr. Clara D. Bloomfield.
In Brief
- Roswell Park signs on to participate in ASCO’s CancerLinQ
- IASLC names research award after Fred R. Hirsch
- Dunmire, Godfrey, Nissenbaum named to LLS leadership team
- Research!America: Republicans, Democrats should prioritize research investment
- John Sampson named president of the Duke Health physician practice
- 49 cancer care facilities receive outstanding achievement award from American College of Surgeons Commission on Cancer
- Fox Chase Cancer Center announces name, recertification for Palliative Care Program
Clinical Roundup
- Cancer survival rates improve for young adults
- Colorectal cancer burden shifts to younger adults
- Phase III BOSTON study meets primary endpoint with significant increase in PFS
- Keytruda meets PFS primary endpoint in phase III KEYNOTE-204
- From scorpion to immunotherapy: City of Hope scientists repurpose toxin for first-of-its kind CAR-T cell therapy for brain tumors
- VBI Vaccines phase I/II study demonstrates OS benefit for VBI-1901 vaccine responders in recurrent GBM
Drugs & Targets
- FDA approves Sarclisa in patients with previously treated MM
- FDA grants RMAT designation for CD30 CAR-T cell therapy in Hodgkin lymphoma indication
- FDA grants tipifarnib Fast Track designation in T-cell lymphomas
- Thermo Fisher Scientific to acquire QiagenN.V.
NCI Trials
NCI Trials for March 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Issue 9 - Feb 28, 2020

TCL46-09 (217 downloads)

ODAC: Thumbs up for Eli Lilly’s Cyramza, thumbs down for STEBA’s Tookad
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
FDA approved 11 new agents, 30 supplemental indications in cancer in 2019
Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.
In Brief
- Jennifer Cullen named associate director of Cancer Population Sciences at Case CCC
- Aaron Gerds named medical director of Clinical Research Office at Case CCC
- Cantley, Bernstein, Pui receive Medal of Honor award from ACS
Clinical Roundup
- Immunotherapy combination effective for patients with high-grade neuroendocrine cancer
- Definitions of malnutrition apply differently depending on cancer type
Drugs & Targets
- FDA approves neratinib for metastatic HER2-positive breast cancer
- FDA accepts sNDA for Zejula in ovarian cancer indication
- FDA grants RMAT designation to CD30 CAR-T Cell Therapy in hodgkin lymphoma indication
- PMC report: FDA addressed rare diseases, expanded cancer treatment and targeted therapies in 2019
- Boehringer Ingelheim and Trutino Biosciences collaborate to grow cancer immunology portfolio with novel cytokine platform

Issue 8 - Feb 21, 2020

TCL46-08 (224 downloads)

Guest Editorial
Lung-MAP: A five-year recap on the first master protocol trial in cancer research
When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborative—and do it for lung cancer, the leading cause of cancer death in the United States.
Trump grants clemency to Michael Milken, financier whose ideas brought new money & swagger into cancer politics, research
Explaining his decision to grant clemency to the financier Michael Milken, President Trump spoke thus:
“We have Mike Milken, who’s gone around and done an incredible job for the world, with all of his research on cancer, and he’s done this, and he suffered greatly. He paid a big price; paid a very tough price. But he’s done an incredible job.”
Looking Back
25 years ago: Here is The Cancer Letter’s coverage of Michael Milken’s 1995 cancer summit
This story begins our occasional series looking back at the history of oncology since the signing of the National Cancer Act of 1971. The Cancer Letter was founded in 1973.
Coalition of cancer groups urges Congress to include clinical trial-related coverage under Medicaid
A coalition of over 100 cancer groups is urging Congress to include the Clinical Treatment Act (HR-913) in an upcoming health care extenders package, scheduled to be considered this spring.
In Brief
- Pamela Kunz named leader of GI Cancers Program at Yale
- Jennifer Carlson named chair of NCCN’s newly formed Government Affairs committee
- Twelve medical centers form brain tumor research collaborative
- ASCO: Drug repository programs address high costs, access and waste issues when appropriately implemented
Funding Opportunities
DOD Lung Cancer Research Program to announce funding opportunities for FY20
The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program to support innovative, high-impact lung cancer research.
Trials & Tribulations
Lung cancer: Significant progress leads to record annual decrease in cancer mortality
We were recently presented with the new report from American Cancer Society¹ showing the biggest annual decrease in cancer mortality, which was mainly due to decline in smoking, as well as improvements in early detection and treatment.
Clinical Roundup
- Updated CheckMate -025 results demonstrate superior OS, ORR for Opdivo in RCC
- Relapse common in weight-loss surgery patients who quit smoking
Drugs & Targets
- FDA grants capmatinib priority review in NSCLC indication
- FDA grants Breakthrough Therapy Designation for Astellas’ and Seattle Genetics’ agent Padcev in bladder cancer indication
- FDA accepts Valoctocogene Roxaparvovec for Priority Review

Page 14 of 116« First «...10 11 12 131415 16 17 18 19...30 40 50 60 70 80 90 100 110...»Last »